OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a ...

GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.

Getting a drug from initial target discovery to U.S. regulatory approval takes between 10 and 15 years on average. Most of ...

The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.

Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI software.

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...

Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going ...

In its announcement, OpenAI called GPT-Rosalind a "frontier reasoning model built to support research across biology, drug ...

By Sahil Pandey and Puyaan Singh April 14 (Reuters) - Amazon's cloud unit on Tuesday launched Amazon Bio Discovery, an ...

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...

The process of discovering new drugs and bringing them to market is notoriously slow and inefficient. Amazon Web Services is ...

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that it says brings together computational ...